Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMP1 CAR-T for LMP1 Positive Infectious Diseases and Hematological Malignancies
NCT04657965Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LMP1 CAR-T in chronic active Epstein-Barr virus infection (CAEBV), Extranodal NK/T-cell lymphoma (ENKTL), Hodgkin lymphoma (HL) and 1 more, sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Incidence of treatment-emergent adverse events at 2 years. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
LMP1 CAR-T
03
Conditions
chronic active Epstein-Barr virus infection (CAEBV)Extranodal NK/T-cell lymphoma (ENKTL)Hodgkin lymphoma (HL)Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT04657965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657965.